You are here

TGA grants provisional determination for COVID-19 vaccine

9 October 2020

14 October 2020: Along with a number of international regulators, the TGA has received and is reviewing preliminary data relating to the safety of this vaccine.

The Therapeutic Goods Administration (TGA), part of the Department of Health, has granted a provisional determination to AstraZeneca Pty Ltd in relation to its COVID-19 Vaccine, ChAd0x1-S [recombinant].

The granting of a provisional determination means that the TGA has made a decision that AstraZeneca is now eligible to apply for provisional registration for the vaccine in the Australian Register of Therapeutic Goods (ARTG).

Provisional determination is the first step in the process and does not mean that an application has or will be made, or that the vaccine will be provisionally approved for inclusion in the ARTG.

Normally for a vaccine to be registered in Australia, a sponsor (usually a pharmaceutical company) is required to submit a complete and comprehensive package of data to the TGA. A formal evaluation is then carried out in multiple stages by technical experts, prior to a decision being made.

The provisional pathway provides a formal and transparent mechanism for speeding up the registration of promising new medicines with preliminary clinical data. In order to apply for provisional registration, the sponsor must first apply for a provisional determination. Further information on eligibility criteria can be found at: Provisional determination: A step-by-step guide for prescription medicines.

In making its decision to grant AstraZeneca a provisional determination, the TGA considered all eligibility criteria, including factors such as the evidence of a plan to submit comprehensive clinical data and the seriousness of the current COVID-19 pandemic.

In addition to this determination, the TGA is actively monitoring COVID-19 vaccine development that is occurring both in Australia and around the world, and is part of a network of international regulators that meet regularly to discuss the development of COVID-19 vaccines and the establishment of systems for monitoring the efficacy and safety of COVID-19 vaccines once they have reached the market. The ability to access early data and planned collaboration with international regulators will assist the TGA to expedite the evaluation of any new vaccines without compromising on our strict requirements for safety, quality and effectiveness of products.